Shares of Texas-based biotechnology company Cassava Sciences, Inc. (SAVA) tumbled 33% on Tuesday after the company reported that its oral drug Simufilam did not yield positive results in patients with ...

The appointment of Dr. Jack Moore as Senior Vice President, Clinical Development brings extensive experience in CNS drug development, which could enhance the company’s initiatives for simufilam and ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to ...

Deep-pocketed investors have adopted a bullish approach towards Cassava Sciences (NASDAQ:SAVA), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Cassava Sciences, Inc. ( ...

Chris Cook, A Skilled Litigator, To Join Management Team as General Counsel New Position Is Expected to Be Critical to Operations and Strategic Initiatives “Chris is an accomplished legal advisor, a ...

Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an issued US method of treatment patent for potential treatment with simufilam ...